Streetbeat News

Stock Prices

SLNO

Soleno Therapeutics, Inc. (NASDAQ:SLNO) has announced its intention to offer and sell shares of its common stock and/or pre-funded warrants in an underwritten public offering. The company also plans to grant underwriters a 30-day option to purchase additional shares equal to 15% of the aggregate number of shares sold in the public offering. Concurrently, Soleno intends to enter into a securities purchase agreement with certain investors for up to $30 million of shares at the public offering price. The completion of the private placement is contingent upon the closing of the public offering. Guggenheim Securities, LLC, Cantor Fitzgerald & Co. and Oppenheimer & Co. Inc. are acting as the joint book-running managers for the public offering and placement agents for the private placement.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 8:10 pm

NAPA

Duckhorn Portfolio (NYSE:NAPA) reported Q4 earnings of $0.15 per share, beating the analyst consensus estimate of $0.13 by 15.38%. This is an 87.5% increase from the same period last year. The company also reported quarterly sales of $100.09 million, beating the estimate of $99.86 million by 0.24%, a 28.31% increase from last year.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 8:09 pm

OPRA

Opera Limited has announced a proposed secondary follow-on public offering of 6.87 million American Depositary Shares (ADS).

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 8:07 pm

FUL

H.B. Fuller (NYSE:FUL) reported Q3 earnings of $1.06 per share, missing the analyst consensus estimate of $1.14 by 7.02%. The company's quarterly sales were $900.63 million, missing the analyst consensus estimate of $956.26 million by 5.82%. This represents a 4.31% decrease over sales of $941.23 million the same period last year.

Portfolio Pulse from Happy Mohamed

September 27, 2023 | 8:06 pm

KF

The Korea Fund, Inc. (NYSE:KF) has appointed Citigroup Global Markets Inc. as its agent and broker for implementing its Discount Management Program. The program allows the fund to repurchase annually up to 10% of its common shares outstanding as of the close of business on June 30th of the prior year. The repurchases will be made on a national securities exchange at the prevailing market price. The program aims to enhance shareholder value by purchasing Fund shares trading at a discount from their net asset value (NAV) per share.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2023 | 8:04 pm

CVS

A significant investor has taken a bullish stance on CVS Health (NYSE:CVS), with 50% of recent trades being bullish and 50% bearish. The total amount for puts is $455,299 and for calls is $356,800. Whales have been targeting a price range from $65.0 to $80.0 for CVS Health over the last 3 months. The current price of CVS is down -2.22% at $69.75. Several experts have given positive ratings and price targets for CVS, ranging from $80 to $87.

Portfolio Pulse from Benzinga Insights

September 27, 2023 | 8:01 pm

FEMY

Femasys Inc. (NASDAQ:FEMY) shares fell by 24% on Wednesday, following a surge in price on Tuesday due to the announcement of FDA 510(k) clearance for FemaSeed, an infertility treatment. The stock experienced an above-average trading volume of 15.73 million shares compared to its average volume of 6.76 million.

Portfolio Pulse from Ryan Gustafson

September 27, 2023 | 8:00 pm

PDD

PDD Holdings (NASDAQ:PDD) has outperformed the market over the past 5 years, producing an average annual return of 29.87%. If an investor had bought $1000 of PDD stock 5 years ago, it would be worth $3,423.98 today.

Portfolio Pulse from Benzinga Insights

September 27, 2023 | 8:00 pm

BSX

Boston Scientific (NYSE:BSX) has outperformed the market over the past 15 years by 1.31% on an annualized basis, producing an average annual return of 10.62%. If an investor had bought $100 of BSX stock 15 years ago, it would be worth $459.48 today.

Portfolio Pulse from Benzinga Insights

September 27, 2023 | 8:00 pm

WTFC

Analysts have provided bullish ratings for Wintrust Finl (NASDAQ:WTFC) within the last quarter, with an average price target of $92.6, implying an upside from the current price of $74.87. The current average has increased by 4.93% from the previous average price target of $88.25.

Portfolio Pulse from Benzinga Insights

September 27, 2023 | 8:00 pm